Neogenomics (NEO) Net Cash Flow (2010 - 2026)

Neogenomics (NEO) has reported Net Cash Flow for 17 consecutive years, with -$13.5 million the latest figure, recorded in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$13.5 million, up 35.27% year-over-year; the trailing twelve-month figure through Mar 2026 was -$200.1 million (down 1500.92% YoY), and the FY2025 annual result was -$207.4 million, down 945.68% from the prior year.
• Net Cash Flow was -$13.5 million for Q1 2026 at Neogenomics, down from -$4.5 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $36.2 million in Q4 2023 and troughed at -$191.4 million in Q2 2025.
• Average Net Cash Flow over 5 years is -$10.0 million, with a median of -$2.9 million recorded in 2022.
• Year-over-year, Net Cash Flow soared 1330.45% in 2023 and tumbled 926.11% in 2025.
• Over 5 years, Net Cash Flow stood at -$2.9 million in 2022, then jumped by 1330.45% to $36.2 million in 2023, then plunged by 86.15% to $5.0 million in 2024, then tumbled by 190.26% to -$4.5 million in 2025, then plunged by 197.4% to -$13.5 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$13.5 million in Q1 2026, -$4.5 million in Q4 2025, and $9.4 million in Q3 2025.